NEWS
Exobiosphere Wins EY Startup World Cup Luxembourg 2025, Heads to Global Finals in San Francisco
(Photo: Emilio Naud/Maison Moderne)
Exobiosphere to Install Orbital High-Throughput Screening Device on Haven-1 Lab
Exobiosphere, the world’s first contract research organization dedicated to drug discovery in space, has raised €2 million in a seed round to scale its orbital high-throughput screening platform.
The round was led by Expansion Ventures, a €200M pan-European venture capital fund backing category-defining founders in aerospace and defence. Significant participation came from Expon Capital, a premier Luxembourg-based firm investing in transformative technologies with the potential to reshape entire industries. The round also attracted Space Data Inc., a cutting-edge Japanese company pioneering real-time digital twin technology for Earth and space systems.
Exobiosphere raises €2M seed round to bring drug discovery to space
Exobiosphere, the world’s first contract research organization dedicated to drug discovery in space, has raised €2 million in a seed round to scale its orbital high-throughput screening platform.
The round was led by Expansion Ventures, a €200M pan-European venture capital fund backing category-defining founders in aerospace and defence. Significant participation came from Expon Capital, a premier Luxembourg-based firm investing in transformative technologies with the potential to reshape entire industries. The round also attracted Space Data Inc., a cutting-edge Japanese company pioneering real-time digital twin technology for Earth and space systems.
Exobiosphere secures LuxIMPULSE contract
Exobiosphere Secures LuxIMPULSE Contract to Advance Space-Based Drug Discovery
Exobiosphere has been awarded a LuxIMPULSE contract funded by the Government of Luxembourg, with technical oversight from the European Space Agency and implementation with the Luxembourg Space Agency. This support will drive the development of the Orbital High-Throughput Screener, a space-based drug discovery platform designed to expand research capabilities in oncology, regenerative medicine, and immunotherapy.